Reported 2 months ago
Eli Lilly reported impressive second-quarter earnings, with revenue exceeding estimates by 13%, driven by $4.3 billion in combined sales of GLP-1 drugs Mounjaro and Zepbound. The company's stock rose by over 10% following the news, and it revised its full-year revenue outlook upwards by $5 billion due to eased supply constraints. Analysts noted that continued demand for GLP-1s and ongoing clinical trials for new drug forms signal a positive future for the company.
Source: YAHOO